The global onychomycosis treatment market is expected to hold a value worth US$ 4,738.3 million in 2023. From 2023 to 2033, the onychomycosis treatment market is likely to exhibit a CAGR of 8.4% while garnering a value worth US$ 10,608.8 million. The market's growth can be attributed to the growing prevalence of diabetes, which results in high risks of nail fungus infection.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 4,738.3 million |
| Anticipated Forecast Value (2033) | US$ 10,608.8 million |
| Projected Growth Rate (2023 to 2033) | 8.4% |
Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can result in chronic pain, disfigurement, and discomfort. The disease is characterized by symptoms such as whitish to yellow-brown discoloration, distortion in the shape of nails, and ragged and crumbly texture of the nails.
It is generally diagnosed through potassium, oxygen, and hydrogen examination, culture, and histopathological examinations of nail clippings and nail biopsies and is treated with laser therapy and photodynamic therapies.
The growing prevalence of chronic illnesses like human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), and onychomycosis is one of the key factors driving the market growth during the forecast period. Also, the expanding geriatric population, prone to such disorders due to the weakened immune system, is likely to fuel the demand for treatment during the forecast period.
Besides, the condition is highly prevalent among millennials and adults owing to the rising exposure to public swimming pools and the usage of tight clothes, shoes, and socks. Other factors adding to the market growth include topical nail lacquers and ointments to maintain nail hygiene, along with the significant developments in the healthcare infrastructure as likely to augment the market size in the forthcoming time.
Additionally, increasing approvals for novel products in the industry are expected to grow the market in the assessment period. For instance, in 2022, Zydus Lifesciences received approval from the US health regulator to market an antifungal Efinaconazole Topical Solution. The company received the final approval from the United States FDA to market the product. Such factors are likely to widen the market growth scope during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The expansion of the market can be attributed to increasing awareness about the threats of onychomycosis and increasing adoption of drug therapies, which are likely to have contributed significantly to the development of the market.
Further, increasing cases of age-related onychomycosis is another cause that is expected to have benefitted the market. Also, increasing approval by the regulatory authorities is another vital factor that has contributed to the market growth. For instance, in July 2021, Lupin received approval to launch Tavaborole Topical Solution, 5 % in the United States from the United States FDA.
Tavaborole Topical Solution is a generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails owing to Trichophyton rubrum or Trichophyton mentagrophytes.
From 2023 to 2033, the global onychomycosis treatment market is anticipated to display a CAGR of 8.4%. The expansion of the market during the aforementioned period can be attributed to the increasing prevalence of diabetes across the globe. Diabetic patients are susceptible to toenail fungus.
Various studies and research have been performed to understand whether diabetic people experience a greater risk of onychomycosis than those without diabetes; most studies concluded that they do. Such factors are expected to benefit the market during the forecast period.
Increasing Shift toward Topical Solutions to Benefit the Market
As per the analysis, the increasing preference for topical treatment solutions is expected to play a significant role in developing the market during the forecast period. Per a survey conducted on dermatologists and podiatrists in the United States, 7 out of 10 doctors avoid prescribing oral terbinafine due to the risk of liver damage.
Another factor contributing to the market growth is the increasing prevalence of toenail infection caused due to onychomycosis. As per a study, about 10% of the world’s general population suffers from onychomycosis, with 35 to 40 million Americans being infected with nail fungus. This is anticipated to favor market growth in the coming time.
Also, the growing approval of medications by the regulatory authorities is anticipated to augment the market size significantly during the forecast period.
For instance, in 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, obtained FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails. Such factors are expected to benefit the market during the forecast period.
Principal Consultant
Lack of Awareness to Hinder the Market
The most significant factor affecting the market negatively includes the lack of awareness regarding the condition. People tend to ignore the symptoms of onychomycosis, such as decolorization, thickening of the nails, and separation of nails from the nail bed.
Because of this, the nail fungal infection remains undiagnosed. Further, people refrain from the treatment as they are not aware of the prevailing condition. Thus, the market is likely to suffer in the coming time. Another factor hampering the market is the side effects of the onychomycosis treatment drugs. Thus, the market is projected to suffer in the assessment period.
Increasing Research and Development Investment by Pharmaceutical Companies to Offer Remunerative Opportunities
The disease's growing prevalence has resulted in a significant investment in research and development by pharmaceutical companies for the development of novel therapeutics. Various available topical treatment solutions fail to penetrate deep inside the nail bed and, thus, do not cure the infection completely. Various players are investing significantly to offer novel drugs to meet the growing demand to cure the condition.
For instance, Hexima is conducting a phase I/IIa clinical study on HXP124, a plant defensin anti-fungal molecule for dermatophytes onychomycosis treatment. HXP124 witnessed a greater penetration rate as compared to Jublia and Kerydin. Such factors are anticipated to offer remunerative opportunities for expansion in the forthcoming time.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of Medicines in Hospitals to Benefit the Segmental Growth in the Forecast Period
According to the analysis, the hospital segment is anticipated to be valued at more than US$ 2.2 Billion in 2022. The development of the segment can be attributed to the availability of medicines and other medical facilities there.
Also, an increase in privately owned clinics and the rise in dermatologists and podiatrists are likely to develop the segment in the forecast period.
Increasing Research and Development on Drugs to Favor Segmental Growth
| Segment | Drugs |
|---|---|
| Market Share % (2022) | 59.4% |
According to the analysis, the drug segment is expected to claim more than 59.4% of the global revenue during the forecast period. The domination of the segment can be attributed to the increasing focus on research and development and the convenience of this treatment type. Thus, the segment is likely to witness notable growth during the forecast period.
| Region | North America |
|---|---|
| Market Share % (2022) | 33.6% |
According to the analysis, the onychomycosis treatment market in North America is expected to dominate the global market during the forecast period. The region is projected to account for a more than 33.6% market share in 2023.
The United States is anticipated to significantly contribute to developing the industry in the assessment period. The domination of the regional market can be attributed to the increasing initiatives of players to study the disease.
For instance, in October 2020, Pfizer Inc. announced that it had commenced clinical studies on onychomycosis. The first phase involved research on whether the AN2690 topical solution is effective for onychomycosis of the toenail.
The second stage involved an open-label study to understand the safety and pharmacokinetics of the tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in children and adolescents.
Another factor contributing to the market growth is the increasing cases of diabetes. As per CDC, 37.3 million Americans, or 1 in 10, have diabetes. Such stats are expected to benefit the market in the forecast period.
| Region | Europe |
|---|---|
| Market Share % (2022) | 28.8% |
As per the study, the European onychomycosis treatment market is anticipated to display a market share of more than 28.8% in 2023. The United Kingdom is projected to make a significant contribution to developing the regional market during the forecast period. The development of the regional market can be attributed to the growing initiatives by the government to spread awareness among citizens.
For instance, the British Association of Dermatologists offers patient information leaflets for fungal infections of the nails. Such factors are expected to benefit the onychomycosis treatment market in Europe during the forecast period.
| Countries | Market Share % (2022) |
|---|---|
| China | 13.2% |
| India | 10.8% |
According to the study, the Asia Pacific is projected to exhibit maximum market growth during the forecast period. The rapid development of the regional market can be attributed to various developing countries making significant contributions to advancing healthcare services.
For instance, in 2020, Kaken Pharmaceuticals Co., Ltd. announced the launch of Jublia in Hong Kong for dermatophytic onychomycosis treatment. Such initiatives are expected to drive the market in the Asia Pacific during the forecast period.
Blueberry Therapeutics, Richpoint Pharma (Canada), ToeFX (Canada), and Hallux (US) are emerging names in the global onychomycosis treatment industry.
Recent Development in the Startup Landscape
In December 2020, Hallux, a United States-based player, completed a US$ 7.1 million Series A expected to allow it to conduct Phase IIa clinical trials of its drug/device combination product for onychomycosis.
Key players in the global onychomycosis treatment market include Teva Pharmaceutical Industries Ltd., Sanofi S.A., Valent Pharmaceutical, Galderma, Johnson & Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health, Inc., Pfizer Inc., Almirall, S.A., Bayer AG, Viatris Inc., GlaxoSmithKline plc, Cipla Ltd., and Dr. Reddy’s Laboratories Ltd.
Recent Developments in the Market Include
| Attributes | Details |
|---|---|
| Onychomycosis Treatment Market Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Onychomycosis Treatment Market Analysis | US$ million in value |
| Onychomycosis Treatment Market - Key Regions Covered |
|
| Key Countries Covered |
|
| Onychomycosis Treatment Market - Key Segments Covered |
|
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, brand share analysis, competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The onychomycosis treatment market is worth US$ 4,738.3 million in 2023.
The onychomycosis treatment market is predicted to rise at an 8.4% CAGR through 2033.
The onychomycosis treatment market is estimated to be worth US$ 10,608.8 million by 2033.
The drugs segment leads the onychomycosis treatment market with 59.4% shares acquired in 2022.
China holds prominence, with 13.2% of shares captured in 2022.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 5.3.1. Drugs 5.3.1.1. Oral 5.3.1.2. Topical 5.3.2. Lasers 5.3.2.1. C02 Ablative Lasers 5.3.2.2. Nd: YAG Lasers 5.3.2.3. Dual-wavelength near-infrared Lasers 5.3.3. Photodynamic Therapy 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033 6.3.1. Distal Subungual Onychomycosis 6.3.2. White Superficial Onychomycosis 6.3.3. Proximal Subungual Onychomycosis 6.3.4. Candidal Onychomycosis 6.3.5. Total Dystrophic Onychomycosis 6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033 7.3.1. 0-18 Years 7.3.2. 18-39 Years 7.3.3. 40-64 Years 7.3.4. 65 Years & Above 7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033 8.3.1. Male 8.3.2. Female 8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 9.3.1. Institutional Sales 9.3.1.1. Hospitals 9.3.1.2. Dermatology Clinics 9.3.2. Retail Sales 9.3.2.1. Retail Pharmacies 9.3.2.2. Drug Stores 9.3.2.3. Mail Order Pharmacies & Online Sales 9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Western Europe 10.3.4. Eastern Europe 10.3.5. South Asia and Pacific 10.3.6. East Asia 10.3.7. Middle East and Africa 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. USA. 11.2.1.2. Canada 11.2.2. By Treatment Type 11.2.3. By Disease Indication 11.2.4. By Age Group 11.2.5. By Gender 11.2.6. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Disease Indication 11.3.4. By Age Group 11.3.5. By Gender 11.3.6. By Distribution Channel 11.4. Key Takeaways 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Treatment Type 12.2.3. By Disease Indication 12.2.4. By Age Group 12.2.5. By Gender 12.2.6. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Disease Indication 12.3.4. By Age Group 12.3.5. By Gender 12.3.6. By Distribution Channel 12.4. Key Takeaways 13. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom. 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Western Europe 13.2.2. By Treatment Type 13.2.3. By Disease Indication 13.2.4. By Age Group 13.2.5. By Gender 13.2.6. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Disease Indication 13.3.4. By Age Group 13.3.5. By Gender 13.3.6. By Distribution Channel 13.4. Key Takeaways 14. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Poland 14.2.1.2. Russia 14.2.1.3. Czech Republic 14.2.1.4. Romania 14.2.1.5. Rest of Eastern Europe 14.2.2. By Treatment Type 14.2.3. By Disease Indication 14.2.4. By Age Group 14.2.5. By Gender 14.2.6. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By Disease Indication 14.3.4. By Age Group 14.3.5. By Gender 14.3.6. By Distribution Channel 14.4. Key Takeaways 15. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. India 15.2.1.2. Bangladesh 15.2.1.3. Australia 15.2.1.4. New Zealand 15.2.1.5. Rest of South Asia and Pacific 15.2.2. By Treatment Type 15.2.3. By Disease Indication 15.2.4. By Age Group 15.2.5. By Gender 15.2.6. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Treatment Type 15.3.3. By Disease Indication 15.3.4. By Age Group 15.3.5. By Gender 15.3.6. By Distribution Channel 15.4. Key Takeaways 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. China 16.2.1.2. Japan 16.2.1.3. South Korea 16.2.2. By Treatment Type 16.2.3. By Disease Indication 16.2.4. By Age Group 16.2.5. By Gender 16.2.6. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Treatment Type 16.3.3. By Disease Indication 16.3.4. By Age Group 16.3.5. By Gender 16.3.6. By Distribution Channel 16.4. Key Takeaways 17. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. GCC Countries 17.2.1.2. South Africa 17.2.1.3. Israel 17.2.1.4. Rest of MEA 17.2.2. By Treatment Type 17.2.3. By Disease Indication 17.2.4. By Age Group 17.2.5. By Gender 17.2.6. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Treatment Type 17.3.3. By Disease Indication 17.3.4. By Age Group 17.3.5. By Gender 17.3.6. By Distribution Channel 17.4. Key Takeaways 18. Key Countries Market Analysis 18.1. USA. 18.1.1. Pricing Analysis 18.1.2. Market Share Analysis, 2022 18.1.2.1. By Treatment Type 18.1.2.2. By Disease Indication 18.1.2.3. By Age Group 18.1.2.4. By Gender 18.1.2.5. By Distribution Channel 18.2. Canada 18.2.1. Pricing Analysis 18.2.2. Market Share Analysis, 2022 18.2.2.1. By Treatment Type 18.2.2.2. By Disease Indication 18.2.2.3. By Age Group 18.2.2.4. By Gender 18.2.2.5. By Distribution Channel 18.3. Brazil 18.3.1. Pricing Analysis 18.3.2. Market Share Analysis, 2022 18.3.2.1. By Treatment Type 18.3.2.2. By Disease Indication 18.3.2.3. By Age Group 18.3.2.4. By Gender 18.3.2.5. By Distribution Channel 18.4. Mexico 18.4.1. Pricing Analysis 18.4.2. Market Share Analysis, 2022 18.4.2.1. By Treatment Type 18.4.2.2. By Disease Indication 18.4.2.3. By Age Group 18.4.2.4. By Gender 18.4.2.5. By Distribution Channel 18.5. Germany 18.5.1. Pricing Analysis 18.5.2. Market Share Analysis, 2022 18.5.2.1. By Treatment Type 18.5.2.2. By Disease Indication 18.5.2.3. By Age Group 18.5.2.4. By Gender 18.5.2.5. By Distribution Channel 18.6. United Kingdom. 18.6.1. Pricing Analysis 18.6.2. Market Share Analysis, 2022 18.6.2.1. By Treatment Type 18.6.2.2. By Disease Indication 18.6.2.3. By Age Group 18.6.2.4. By Gender 18.6.2.5. By Distribution Channel 18.7. France 18.7.1. Pricing Analysis 18.7.2. Market Share Analysis, 2022 18.7.2.1. By Treatment Type 18.7.2.2. By Disease Indication 18.7.2.3. By Age Group 18.7.2.4. By Gender 18.7.2.5. By Distribution Channel 18.8. Spain 18.8.1. Pricing Analysis 18.8.2. Market Share Analysis, 2022 18.8.2.1. By Treatment Type 18.8.2.2. By Disease Indication 18.8.2.3. By Age Group 18.8.2.4. By Gender 18.8.2.5. By Distribution Channel 18.9. Italy 18.9.1. Pricing Analysis 18.9.2. Market Share Analysis, 2022 18.9.2.1. By Treatment Type 18.9.2.2. By Disease Indication 18.9.2.3. By Age Group 18.9.2.4. By Gender 18.9.2.5. By Distribution Channel 18.10. Poland 18.10.1. Pricing Analysis 18.10.2. Market Share Analysis, 2022 18.10.2.1. By Treatment Type 18.10.2.2. By Disease Indication 18.10.2.3. By Age Group 18.10.2.4. By Gender 18.10.2.5. By Distribution Channel 18.11. Russia 18.11.1. Pricing Analysis 18.11.2. Market Share Analysis, 2022 18.11.2.1. By Treatment Type 18.11.2.2. By Disease Indication 18.11.2.3. By Age Group 18.11.2.4. By Gender 18.11.2.5. By Distribution Channel 18.12. Czech Republic 18.12.1. Pricing Analysis 18.12.2. Market Share Analysis, 2022 18.12.2.1. By Treatment Type 18.12.2.2. By Disease Indication 18.12.2.3. By Age Group 18.12.2.4. By Gender 18.12.2.5. By Distribution Channel 18.13. Romania 18.13.1. Pricing Analysis 18.13.2. Market Share Analysis, 2022 18.13.2.1. By Treatment Type 18.13.2.2. By Disease Indication 18.13.2.3. By Age Group 18.13.2.4. By Gender 18.13.2.5. By Distribution Channel 18.14. India 18.14.1. Pricing Analysis 18.14.2. Market Share Analysis, 2022 18.14.2.1. By Treatment Type 18.14.2.2. By Disease Indication 18.14.2.3. By Age Group 18.14.2.4. By Gender 18.14.2.5. By Distribution Channel 18.15. Bangladesh 18.15.1. Pricing Analysis 18.15.2. Market Share Analysis, 2022 18.15.2.1. By Treatment Type 18.15.2.2. By Disease Indication 18.15.2.3. By Age Group 18.15.2.4. By Gender 18.15.2.5. By Distribution Channel 18.16. Australia 18.16.1. Pricing Analysis 18.16.2. Market Share Analysis, 2022 18.16.2.1. By Treatment Type 18.16.2.2. By Disease Indication 18.16.2.3. By Age Group 18.16.2.4. By Gender 18.16.2.5. By Distribution Channel 18.17. New Zealand 18.17.1. Pricing Analysis 18.17.2. Market Share Analysis, 2022 18.17.2.1. By Treatment Type 18.17.2.2. By Disease Indication 18.17.2.3. By Age Group 18.17.2.4. By Gender 18.17.2.5. By Distribution Channel 18.18. China 18.18.1. Pricing Analysis 18.18.2. Market Share Analysis, 2022 18.18.2.1. By Treatment Type 18.18.2.2. By Disease Indication 18.18.2.3. By Age Group 18.18.2.4. By Gender 18.18.2.5. By Distribution Channel 18.19. Japan 18.19.1. Pricing Analysis 18.19.2. Market Share Analysis, 2022 18.19.2.1. By Treatment Type 18.19.2.2. By Disease Indication 18.19.2.3. By Age Group 18.19.2.4. By Gender 18.19.2.5. By Distribution Channel 18.20. South Korea 18.20.1. Pricing Analysis 18.20.2. Market Share Analysis, 2022 18.20.2.1. By Treatment Type 18.20.2.2. By Disease Indication 18.20.2.3. By Age Group 18.20.2.4. By Gender 18.20.2.5. By Distribution Channel 18.21. GCC Countries 18.21.1. Pricing Analysis 18.21.2. Market Share Analysis, 2022 18.21.2.1. By Treatment Type 18.21.2.2. By Disease Indication 18.21.2.3. By Age Group 18.21.2.4. By Gender 18.21.2.5. By Distribution Channel 18.22. South Africa 18.22.1. Pricing Analysis 18.22.2. Market Share Analysis, 2022 18.22.2.1. By Treatment Type 18.22.2.2. By Disease Indication 18.22.2.3. By Age Group 18.22.2.4. By Gender 18.22.2.5. By Distribution Channel 18.23. Israel 18.23.1. Pricing Analysis 18.23.2. Market Share Analysis, 2022 18.23.2.1. By Treatment Type 18.23.2.2. By Disease Indication 18.23.2.3. By Age Group 18.23.2.4. By Gender 18.23.2.5. By Distribution Channel 19. Market Structure Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Market Share Analysis of Top Players 19.3.1. By Regional 19.3.2. By Treatment Type 19.3.3. By Disease Indication 19.3.4. By Age Group 19.3.5. By Gender 19.3.6. By Distribution Channel 20. Competition Analysis 20.1. Competition Deep Dive 20.1.1. Teva Pharmaceutical Industries Ltd. 20.1.1.1. Overview 20.1.1.2. Product Portfolio 20.1.1.3. Profitability by Market Segments 20.1.1.4. Sales Footprint 20.1.1.5. Strategy Overview 20.1.1.5.1. Marketing Strategy 20.1.2. Sanofi S.A. 20.1.2.1. Overview 20.1.2.2. Product Portfolio 20.1.2.3. Profitability by Market Segments 20.1.2.4. Sales Footprint 20.1.2.5. Strategy Overview 20.1.2.5.1. Marketing Strategy 20.1.3. Medimetriks Pharmaceuticals, Inc. 20.1.3.1. Overview 20.1.3.2. Product Portfolio 20.1.3.3. Profitability by Market Segments 20.1.3.4. Sales Footprint 20.1.3.5. Strategy Overview 20.1.3.5.1. Marketing Strategy 20.1.4. Galderma 20.1.4.1. Overview 20.1.4.2. Product Portfolio 20.1.4.3. Profitability by Market Segments 20.1.4.4. Sales Footprint 20.1.4.5. Strategy Overview 20.1.4.5.1. Marketing Strategy 20.1.5. Johnson & Johnson 20.1.5.1. Overview 20.1.5.2. Product Portfolio 20.1.5.3. Profitability by Market Segments 20.1.5.4. Sales Footprint 20.1.5.5. Strategy Overview 20.1.5.5.1. Marketing Strategy 20.1.6. Novartis AG 20.1.6.1. Overview 20.1.6.2. Product Portfolio 20.1.6.3. Profitability by Market Segments 20.1.6.4. Sales Footprint 20.1.6.5. Strategy Overview 20.1.6.5.1. Marketing Strategy 20.1.7. Moberg Pharma AB 20.1.7.1. Overview 20.1.7.2. Product Portfolio 20.1.7.3. Profitability by Market Segments 20.1.7.4. Sales Footprint 20.1.7.5. Strategy Overview 20.1.7.5.1. Marketing Strategy 20.1.8. Cardinal Health, Inc. 20.1.8.1. Overview 20.1.8.2. Product Portfolio 20.1.8.3. Profitability by Market Segments 20.1.8.4. Sales Footprint 20.1.8.5. Strategy Overview 20.1.8.5.1. Marketing Strategy 20.1.9. Pfizer Inc. 20.1.9.1. Overview 20.1.9.2. Product Portfolio 20.1.9.3. Profitability by Market Segments 20.1.9.4. Sales Footprint 20.1.9.5. Strategy Overview 20.1.9.5.1. Marketing Strategy 20.1.10. Almirall, S.A. 20.1.10.1. Overview 20.1.10.2. Product Portfolio 20.1.10.3. Profitability by Market Segments 20.1.10.4. Sales Footprint 20.1.10.5. Strategy Overview 20.1.10.5.1. Marketing Strategy 20.1.11. Bayer AG 20.1.11.1. Overview 20.1.11.2. Product Portfolio 20.1.11.3. Profitability by Market Segments 20.1.11.4. Sales Footprint 20.1.11.5. Strategy Overview 20.1.11.5.1. Marketing Strategy 20.1.12. Viatris Inc. 20.1.12.1. Overview 20.1.12.2. Product Portfolio 20.1.12.3. Profitability by Market Segments 20.1.12.4. Sales Footprint 20.1.12.5. Strategy Overview 20.1.12.5.1. Marketing Strategy 20.1.13. GlaxoSmithKline plc 20.1.13.1. Overview 20.1.13.2. Product Portfolio 20.1.13.3. Profitability by Market Segments 20.1.13.4. Sales Footprint 20.1.13.5. Strategy Overview 20.1.13.5.1. Marketing Strategy 20.1.14. Cipla Ltd. 20.1.14.1. Overview 20.1.14.2. Product Portfolio 20.1.14.3. Profitability by Market Segments 20.1.14.4. Sales Footprint 20.1.14.5. Strategy Overview 20.1.14.5.1. Marketing Strategy 20.1.15. Dr. Reddy’s Laboratories Ltd 20.1.15.1. Overview 20.1.15.2. Product Portfolio 20.1.15.3. Profitability by Market Segments 20.1.15.4. Sales Footprint 20.1.15.5. Strategy Overview 20.1.15.5.1. Marketing Strategy 21. Assumptions & Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Onychomycosis Treatment Market
